COX-2: A Pivotal Enzyme in Mucosal Protection and Resolution of Inflammation

The discovery of a second form of cyclooxygenase, COX-2, led to a burst of research aimed at the development of nonsteroidal anti-inflammatory drugs that would not damage the gastrointestinal tract. In the years since, this promise has only been partially fulfilled. Selective COX-2 inhibitors cause...

Full description

Saved in:
Bibliographic Details
Main Author: John L. Wallace
Format: Article
Language:English
Published: Wiley 2006-01-01
Series:The Scientific World Journal
Online Access:http://dx.doi.org/10.1100/tsw.2006.122
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849737945568772096
author John L. Wallace
author_facet John L. Wallace
author_sort John L. Wallace
collection DOAJ
description The discovery of a second form of cyclooxygenase, COX-2, led to a burst of research aimed at the development of nonsteroidal anti-inflammatory drugs that would not damage the gastrointestinal tract. In the years since, this promise has only been partially fulfilled. Selective COX-2 inhibitors cause less gastric damage than conventional, nonselective COX inhibitors, but their use is still associated with significant gastrointestinal injury, and with toxicity in the renal and cardiovascular systems. COX-2 is now recognized as a source of mediators that produce many beneficial and detrimental effects in the digestive system. In this review, the roles of COX-2 in mucosal defense and injury are discussed. Furthermore, contributions of COX-2derived products to the long-term consequences of intestinal inflammation, including cancer, are reviewed.
format Article
id doaj-art-8229b40b4cbf45a0aa9f6453a4ef229c
institution DOAJ
issn 1537-744X
language English
publishDate 2006-01-01
publisher Wiley
record_format Article
series The Scientific World Journal
spelling doaj-art-8229b40b4cbf45a0aa9f6453a4ef229c2025-08-20T03:06:46ZengWileyThe Scientific World Journal1537-744X2006-01-01657758810.1100/tsw.2006.122COX-2: A Pivotal Enzyme in Mucosal Protection and Resolution of InflammationJohn L. Wallace0Inflammation Research Network, Department of Pharmacology and Therapeutics, University of Calgary, Calgary, Alberta, T2N 4N1, CanadaThe discovery of a second form of cyclooxygenase, COX-2, led to a burst of research aimed at the development of nonsteroidal anti-inflammatory drugs that would not damage the gastrointestinal tract. In the years since, this promise has only been partially fulfilled. Selective COX-2 inhibitors cause less gastric damage than conventional, nonselective COX inhibitors, but their use is still associated with significant gastrointestinal injury, and with toxicity in the renal and cardiovascular systems. COX-2 is now recognized as a source of mediators that produce many beneficial and detrimental effects in the digestive system. In this review, the roles of COX-2 in mucosal defense and injury are discussed. Furthermore, contributions of COX-2derived products to the long-term consequences of intestinal inflammation, including cancer, are reviewed.http://dx.doi.org/10.1100/tsw.2006.122
spellingShingle John L. Wallace
COX-2: A Pivotal Enzyme in Mucosal Protection and Resolution of Inflammation
The Scientific World Journal
title COX-2: A Pivotal Enzyme in Mucosal Protection and Resolution of Inflammation
title_full COX-2: A Pivotal Enzyme in Mucosal Protection and Resolution of Inflammation
title_fullStr COX-2: A Pivotal Enzyme in Mucosal Protection and Resolution of Inflammation
title_full_unstemmed COX-2: A Pivotal Enzyme in Mucosal Protection and Resolution of Inflammation
title_short COX-2: A Pivotal Enzyme in Mucosal Protection and Resolution of Inflammation
title_sort cox 2 a pivotal enzyme in mucosal protection and resolution of inflammation
url http://dx.doi.org/10.1100/tsw.2006.122
work_keys_str_mv AT johnlwallace cox2apivotalenzymeinmucosalprotectionandresolutionofinflammation